- Conditions
- Retinitis Pigmentosa, Leber Congenital Amaurosis
- Interventions
- OCU400 Low Dose, OCU400 Med Dose, OCU400 High Dose, OCU400 Second Eye Dosing
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • La Jolla, California • Miami, Florida + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 257
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-exudative Age-related Macular Degeneration, Diabetic Retinopathy, Retina Vein Occlusion, Retinitis Pigmentosa, Hereditary Macular Degeneration
- Interventions
- CD34+ bone marrow stem cells intravitreal
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Retinal Disease, Age-Related Macular Degeneration, Retinitis Pigmentosa, Stargardt Disease, Optic Neuropathy, Nonarteritic Ischemic Optic Neuropathy, Optic Atrophy, Optic Nerve Disease, Glaucoma, Leber Hereditary Optic Neuropathy, Blindness, Vision Loss Night, Vision Loss Partial, Vision, Low, Retinopathy, Maculopathy, Macular Degeneration, Retina Atrophy
- Interventions
- Arm 1
- Procedure
- Lead sponsor
- MD Stem Cells
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2028
- U.S. locations
- 2
- States / cities
- Westport, Connecticut • Coral Springs, Florida
- Conditions
- Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
- Interventions
- Biological sample collection
- Other
- Lead sponsor
- New York Stem Cell Foundation Research Institute
- Other
- Eligibility
- 1 Month to 100 Years
- Enrollment
- 1,279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV
- Interventions
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, Aflibercept (EYLEA®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 735 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 107
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 94 more
- Conditions
- Stargardt's Macular Dystrophy
- Interventions
- avacincaptad pegol, Sham
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Gainesville, Florida + 14 more
- Conditions
- Dry Age-related Macular Degeneration, Macular Degeneration, Retinal Disease, Retinal Degeneration, Geographic Atrophy, Macular Atrophy
- Interventions
- Not listed
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 29 more
- Conditions
- Healthy, Muscular Dystrophy, Retinal Degeneration, Skin Diseases, Virus Diseases
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1978 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- AKST4290, Placebo, Aflibercept
- Drug
- Lead sponsor
- Alkahest, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Retinal Dystrophies
- Interventions
- SS-HH-OCT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 8 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stargardt, Stargardt's Disease, Stargardt Disease, STGD1
- Interventions
- Not listed
- Lead sponsor
- Splice Bio
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 14
- States / cities
- San Diego, California • Aurora, Colorado • Gainesville, Florida + 10 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Not listed
- Lead sponsor
- Second Sight Medical Products
- Industry
- Eligibility
- 25 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Denver, Colorado • Miami, Florida + 13 more
- Conditions
- Confirmed Biallelic RPE65 Mutation-associated Retinal Dystrophy
- Interventions
- AAV2-hRPE65v2,voretigene neparvovec-rzyl
- Biological
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Iowa City, Iowa + 6 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- NG101 AAV gene therapy
- Genetic
- Lead sponsor
- Elisigen, Inc.
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration, Neovascularization, Pathologic
- Interventions
- OPT-302, Lucentis™
- Drug
- Lead sponsor
- Opthea Limited
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 11 more
- Conditions
- Diabetic Retinopathy
- Interventions
- Tarcocimab, Sham injection
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 38
- States / cities
- Tucson, Arizona • Fullerton, California • Glendale, California + 34 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- human retinal progenitor cells, Mock injection
- Biological · Other
- Lead sponsor
- jCyte, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 9 more
- Conditions
- Optic Atrophy, Non-arteritic Anterior Ischemic Optic Neuropathy
- Interventions
- QPI-1007 at various doses
- Drug
- Lead sponsor
- Quark Pharmaceuticals
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
- Conditions
- Geographic Atrophy, Stargardt Disease, RPE-mediated Maculopathy, Age Related Macular Degeneration
- Interventions
- Injection
- Biological
- Lead sponsor
- Cellio Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Beverly Hills, California • Palo Alto, California • Sacramento, California
- Conditions
- Retinitis Pigmentosa
- Interventions
- Object recognition subsystem
- Device
- Lead sponsor
- Minnesota HealthSolutions
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Stargardt Disease
- Interventions
- Emixustat, Placebo
- Drug
- Lead sponsor
- Kubota Vision Inc.
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 194 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Beverly Hills, California • San Francisco, California • Atlanta, Georgia + 8 more
- Conditions
- Retinitis Pigmentosa, Stargardt Macular Dystrophy, Stargardt Disease, Geographic Atrophy From Age-related Macular Degeneration, X-linked Retinoschisis, Retinal Dystrophies
- Interventions
- Not listed
- Lead sponsor
- Ray Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Retinopathy of Prematurity, Neurodevelopmental Disorders, Macular Edema
- Interventions
- Swept Source OCT, Magnetic Resonance Imaging, Scavenged blood collection
- Device · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 30 Weeks and older
- Enrollment
- 191 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2021
- U.S. locations
- 4
- States / cities
- Gainesville, Florida • St Louis, Missouri • Durham, North Carolina + 1 more